At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 183 enrolled
Drug / intervention
ADCT-402drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
In Brief
A Phase 1 clinical trial evaluating ADCT-402 for Non-Hodgkin Lymphoma and 8 related conditions. Completed, enrolled 183 participants across 11 sites in 3 countries.
Detailed Summary
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose level identified in Part 1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma
CountriesItaly, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionFeb 2019
TodayJul 2026
First PostedJan 29, 2016
Enrollment StartMar 1, 2016
Primary CompletionFeb 21, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.4 years ago
Interventions
ADCT-402drug
intravenous infusion